Accessibility Menu
IceCure Medical logo

IceCure Medical(NASDAQ) ICCM

Market Cap$8.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2013)+0%
5 Year-99%
1 Year-88%
1 Month-16%
$3.09
+3.00%
+0.09Today
After hours$2.96-$0.13 (-4.21%)
IceCure Medical last closing stock price
MetricPriceDate
Last closeUSD 3.022026-08-14
IceCure Medical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.95%USD 3.082026-08-07
1 month-16.11%USD 3.602026-07-15
3 month-56.19%USD 6.892026-05-15
Year to date-83.5%USD 18.302025-12-31
1 year-88.04%USD 25.252025-08-14
3 year-90.03%USD 30.302023-08-15
5 year-99.07%USD 324.002021-08-13
Since inception+0.2%USD 3.012013-11-07

IceCure Medical Financials at a Glance

Market Cap

$8.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$3.95M

Net Income (TTM)

-$16.88M

EPS (TTM)

-$6.57

P/E Ratio

-0.46

Dividend

$0.00

Beta (Volatility)

0.79 (Low)

Price

$3.09

Volume

50,756.309

Open

$3.04

Previous Close

$3.02

Daily Range

$2.96 - $3.20

52-Week Range

$2.12 - $42.00

Estimated Earnings Date

Nov 18, 2026

ICCM News

featured-earnings-leadership-highlights.png

IceCure Medical Advances FDA Review

Motley Fool Markets TeamAug 13, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About IceCure Medical

IceCure Medical Ltd is a medical device company based in Caesarea, Israel, specializing in innovative solutions for tumor treatment through cryoablation. Founded in 2006, the company focuses on developing and marketing its primary product, the ProSense system, which offers specialized cryoablation therapy for breast tumors.

Products and Services
  • ProSense system for cryoablation therapy
  • Innovative solutions for tumor treatment
  • Research and development in medical devices
Growth Outlook
  • Recent quarterly revenue increased to $911,000
  • Cash and cash equivalents at $8.1 million as of March 2026
  • Current ratio of 2.52 indicates strong liquidity position
Financial Highlights
  • Trailing twelve months revenue of $3.5 million
  • Net income for Q1 2026 reported at -$4.27 million
  • Operating expenses totaled $4.54 million in Q1 2026
IceCure Medical Ltd is positioned in the healthcare sector, focusing on medical devices that address significant health challenges. The ProSense system represents a cutting-edge approach to tumor treatment, leveraging cryoablation technology. The company has shown resilience with a notable increase in quarterly revenue, reflecting growing market interest and potential for expansion. The liquidity position, indicated by a current ratio of 2.52, suggests that IceCure Medical is well-equipped to manage its short-term obligations. Despite reporting a net loss, the company continues to invest in research and development, aiming to enhance its product offerings and market reach. The financial data indicates a commitment to growth, making IceCure Medical an intriguing option for investors interested in innovative healthcare solutions.
AI Generated • Jul 23, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

69

CEO

Eyal Shamir, MBA

Website

www.icecure-medical.com

Headquarters

Caesarea, HA 3079504, IL

ICCM Financials

Key Financial Metrics (TTM)

Gross Margin

36.10%

Operating Margin

-556.35%

Net Income Margin

-427.67%

Return on Equity

-174.26%

Return on Capital

-162.86%

Return on Assets

-95.33%

Earnings Yield

-2.17%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$8.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.81M

Volume

50.76K

Avg. Volume

3.29M

Financials (TTM)

Gross Profit

$1.43M

Operating Income

-$21.96M

EBITDA

-$16.44M

Operating Cash Flow

-$16.32M

Capital Expenditure

-$69.77K

Free Cash Flow

-$16.39M

Cash & ST Invst.

$12.03M

Total Debt

$90.00K

IceCure Medical Performance Analysis

IceCure Medical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 3,085,000-25.4%
20232023-12-31USD 3,229,0004.7%
20242024-12-31USD 3,291,0001.9%
20252025-12-31USD 3,379,0002.7%
IceCure Medical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3061.9%
Q42025-12-3150.5%
Q12026-03-31-28.8%
Q22026-06-30-0.4%
IceCure Medical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -13.5032.3%
20232023-12-31USD -9.45-30.0%
20242024-12-31USD -8.86-6.2%
20252025-12-31USD -7.10-19.8%
IceCure Medical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-5.4%
Q42025-12-313.5%
Q12026-03-310.5%
Q22026-06-3016.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$907.00K

+72.8%

Gross Profit

$253.00K

+93.1%

Gross Margin

27.89%

N/A

Market Cap

$8.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$124.65K

N/A

Employees

68

N/A

Net Income

-$4.50M

-33.8%

EBITDA

-$4.35M

-31.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$12.03M

+123.6%

Total Debt

$90.00K

-96.2%

Accounts Receivable

$413.00K

-68.4%

Inventory

$2.55M

+9.3%

Long Term Debt

$21.00K

-64.4%

Short Term Debt

$69.00K

-97.0%

Return on Assets

-95.33%

N/A

Return on Invested Capital

-1.84%

N/A

Free Cash Flow

-$3.89M

-37.2%

Operating Cash Flow

-$3.88M

-37.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MDCXMedicus Pharma Ltd. Common Stock
$0.28-20.88%
CTSOCytosorbents Corporation
$0.40+10.38%
TELATELA Bio, Inc.
$0.64-4.97%
PETSPetMed Express, Inc.
$1.83-10.10%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.23+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76+0.01%
ONDSOndas
$9.24+0.04%
SPCXSpace Exploration Technologies
$140.00-0.01%

Questions About ICCM

What is the current price of IceCure Medical?

IceCure Medical is trading at $3.02 per share.

What is the 52-week range for IceCure Medical?

Over the past 52 weeks, IceCure Medical has traded between $2.12 and $42.00.

How much debt does IceCure Medical have?

As of the most recent reporting period, IceCure Medical reported total debt of $90.00K.

How much cash does IceCure Medical have on hand?

IceCure Medical reported $12.03M in cash and cash equivalents in its most recent financial results.

What is IceCure Medical’s dividend yield?

IceCure Medical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services